After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...
Central Cee & Dave look to score the highest new entry on this week’s Official Singles Chart with CRG (an abbreviation of CAN ...
The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...
Jefferies downgraded Cargo Therapeutics (CRGX) to Hold from Buy with a price target of $3, down from $32. The company announced the “surprising ...
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...
Kangkan Kalita is a reporter with The Times of India and covers issues on health, education, stories of human interest while ...
Investing.com -- Shares of CARGO Therapeutics , Inc. (NASDAQ: CRGX) plummeted 75% following the company's decision to discontinue its Phase 2 clinical trial for firicabtagene autoleucel, citing ...
CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a mid-stage trial of its lead program, firi-cel.
Vibe on MSN4h
Central Cee Explains Why He Preferred Not Having Drake Feature On Debut Album ‘Can't Rush Greatness'Central Cee has worked hard to get himself to the brink of stardom, but, like many artists, he received a boost from Drake ...
CARGO Therapeutics stock has reached a new 52-week low, trading at $3.09 with a market capitalization of $607 million, as ...
Central Cee’s ascent over the past five years has been staggering, even by the accelerated standards of TikTok stardom. He arrived on the scene in 2020, and, aided by an acute s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback